Evaluation of the Relationship Between Advanced Oxidation end Products and Inflammatory Markers in Maintenance Hemodialysis Patients

Abstract

Introduction Increased oxidative stress and blunted anti-oxidant mechanisms are important problems in hemodialysis (HD) patients. Reactive oxygen species (ROS) act directly on proteins, leading to the formation of oxidized amino acids. Advanced oxidation protein products (AOPP) are among these substances. Many oxidant substances increase the level of AOPP. Iron is an element with strong oxidant capacity, especially when used intravenously. It is thought that iron treatment further increases the oxidative stress in HD patients. We aimed to investigate the relationship between AOPP and inflammatory status in HD patients. Materials and Methods Patients who were on maintenance HD program without additional co-morbidities and no history of use of intravenous iron within the last two weeks were recruited in the study. The blood samples taken just before the dialysis session were analyzed for AOPP, serum iron, total iron binding capacity (TIBC), ferritin, C-reactive protein (CRP), ß2-microglobulin, fibrinogen, interleukin (IL)-1, IL-6 and tumor necrosis factor-α levels besides routine biochemical measurements and complete blood count. Results The number of patients included in the study was 102 (n: 53 female, %52.0) and the mean age was 47.6±13.9 years. The mean transferrin saturation was 25.4%. AOPP levels, iron use in patients was higher compared to patients who do not use (respectively 2.58±0.19 mmol/l and 2.50 ±0.16mmol/l, p = 0.046). We did not detect statistically significant correlation of AOPP levels with iron parameters and other inflammatory markers. Conclusion The present study showed that intravenous iron therapy does not increase oxidative stress. Although serum AOPP level was higher in patients on intravenous iron treatment, it was not correlated with iron indices and inflammatory markers. So, intravenous iron may exert its oxidant effect free from serum iron indices.

Proanthocyanidins Protect Against Cadmium-Induced Diabetic Nephropathy Through p38 MAPK and Keap1/Nrf2 Signaling Pathways

“…The progression of DN, one of the biggest problems in nephrology field, pointing to that patients progress end-stage renal disease and require dialysis ( Aydin et al, 2019 ; Bacharaki et al, 2021 ) or kidney transplantation ( Webster et al, 2017 ; Jain et al, 2019 ; Van Sandwijk et al, 2019 ). Recent epidemiological studies reveal a link between Cd exposure and the incidence of diabetes and its complications ( Chen et al, 2006 ; Afridi et al, 2008 ; Akinloye et al, 2010 ; Satarug et al, 2010 ; Wallin et al, 2014 ).…”

Shenkang Injection and Its Three Anthraquinones Ameliorates Renal Fibrosis by Simultaneous Targeting IƙB/NF-ƙB and Keap1/Nrf2 Signaling Pathways

“…The progression of CKD and renal fibrosis, one of the biggest issues in nephrology, indicated that patients inevitably progress ESRD and require dialysis or kidney transplantation ( Webster et al, 2017 ; Aydin et al, 2019 ; Van Sandwijk et al, 2019 ). Numerous studies have demonstrated that renal fibrosis was associated with the dysbiosis or dysregulation of gut microbiota, non-coding RNAs, renin–angiotensin system, aryl hydrocarbon receptor, IƙB/NF-ƙB, Keap1/Nrf2, TGF-β/Smad, and Wnt/β-catenin signaling pathways ( Ma et al, 2018a ; Chen et al, 2019b ; Garg and Maurya, 2019 ; Zhao et al, 2019 ; Hu et al, 2020a ; Miao et al, 2021b ; Wang et al, 2021d ; Wu et al, 2021 ; Zhou et al, 2021 ) as well as metabolite disorders including tryptophan metabolism and lipid metabolism ( Zhao, 2013a ; Zhao et al, 2015 ; Wang et al, 2019 ; Liu et al, 2021a ).…”

TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis

“…Moreover, with the progression of CKD, it can easily lead to the occurrence of cardiovascular diseases ( Ravid et al, 2021 ). Renal fibrosis, characterized by tubulointerstitial fibrosis and glomerulosclerosis, is the common pathway and inevitable outcome of various progression of CKD to end-stage renal disease (ESRD) and need renal replacement treatments such as dialysis and transplantation ( Humphreys, 2018 ; Aydin et al, 2019 ; Jain et al, 2019 ; Carta et al, 2020 ; Sawhney and Gill, 2020 ). Regardless of the underlying diseases, it has been demonstrated that patient’s survival is associated with tubulointerstitial fibrosis ( Tampe and Zeisberg, 2014 ) and the extent of tubulointerstitial fibrosis on renal biopsy is thought as a prognostic indicator for CKD treatment ( Tang et al, 2019 ).…”